HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Shihui Liu Selected Research

anthrax toxin (anthrax lethal factor)

1/2020Inhibitory Effects of a Reengineered Anthrax Toxin on Canine Oral Mucosal Melanomas.
1/2020Inhibitory Effects of a Reengineered Anthrax Toxin on Canine and Human Osteosarcoma Cells.
1/2019Bismaleimide cross-linked anthrax toxin forms functional octamers with high specificity in tumor targeting.
9/2017Anti-tumor activity of anthrax toxin variants that form a functional translocation pore by intermolecular complementation.
10/2016Anthrax Toxin Protective Antigen Variants That Selectively Utilize either the CMG2 or TEM8 Receptors for Cellular Uptake and Tumor Targeting.
11/2015An anthrax toxin variant with an improved activity in tumor targeting.
10/2015Targeting the membrane-anchored serine protease testisin with a novel engineered anthrax toxin prodrug to kill tumor cells and reduce tumor burden.
4/2013Anthrax toxin-mediated delivery of the Pseudomonas exotoxin A enzymatic domain to the cytosol of tumor cells via cleavable ubiquitin fusions.
3/2013Engineering anthrax toxin variants that exclusively form octamers and their application to targeting tumors.
2/2013Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Shihui Liu Research Topics

Disease

34Neoplasms (Cancer)
11/2021 - 02/2002
33Anthrax
12/2020 - 02/2002
7Melanoma (Melanoma, Malignant)
01/2020 - 08/2003
5Thrombosis (Thrombus)
01/2021 - 05/2014
5Infections
09/2012 - 07/2009
4Retinitis Pigmentosa (Pigmentary Retinopathy)
12/2021 - 01/2017
4Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
10/2015 - 10/2004
4Edema (Dropsy)
01/2015 - 03/2007
2Coronary Disease (Coronary Heart Disease)
04/2022 - 01/2021
2Brain Ischemia (Cerebral Ischemia)
11/2021 - 10/2019
2Reperfusion Injury
11/2021 - 10/2019
2Cardiovascular Diseases (Cardiovascular Disease)
01/2021 - 01/2019
1Cognitive Dysfunction
12/2022
1Hypoxia (Hypoxemia)
08/2021
1Retinal Dystrophies
06/2021
1Wounds and Injuries (Trauma)
01/2021
1Necrosis
01/2020
1Osteosarcoma (Osteogenic Sarcoma)
01/2020
1Ischemia
10/2019
1Stroke (Strokes)
10/2019
1Infarction (Infarctions)
10/2019
1Vascular System Injuries
01/2019
1Coronary Artery Disease (Coronary Atherosclerosis)
01/2019
1Retinal Diseases
01/2017
1Astrocytoma (Pilocytic Astrocytoma)
05/2016
1Atherosclerosis
03/2015
1Aneurysm (Aneurysms)
03/2015
1Rupture
03/2015
1Bacterial Infections (Bacterial Infection)
06/2014
1Colonic Neoplasms (Colon Cancer)
02/2013

Drug/Important Bio-Agent (IBA)

21anthrax toxin (anthrax lethal factor)IBA
01/2020 - 02/2002
18Proteins (Proteins, Gene)FDA Link
12/2022 - 02/2002
12AntigensIBA
12/2020 - 02/2003
12Urokinase-Type Plasminogen Activator (Urokinase)FDA Link
01/2020 - 01/2003
12Matrix Metalloproteinases (MMPs)IBA
10/2019 - 06/2005
9Plasminogen Activators (Plasminogen Activator)IBA
01/2020 - 01/2003
9Peptide Hydrolases (Proteases)FDA Link
09/2017 - 02/2002
7Mitogen-Activated Protein KinasesIBA
10/2015 - 08/2003
7anthrax toxin receptorsIBA
12/2012 - 09/2005
6ExotoxinsIBA
06/2014 - 02/2002
5FurinIBA
10/2019 - 03/2008
5Virulence Factors (Pathogenicity Factors)IBA
01/2015 - 01/2008
5Diphtheria ToxinIBA
07/2009 - 02/2002
4GelatinasesIBA
01/2010 - 03/2008
3InflammasomesIBA
12/2020 - 12/2010
3Phosphotransferases (Kinase)IBA
12/2020 - 09/2005
3Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
12/2020 - 02/2003
3edema factorIBA
01/2015 - 02/2012
22- (2- (4- (dibutylamino)phenyl)ethenyl)- 3- carboxymethylbenzothiazoliumIBA
12/2021 - 06/2021
2PPAR gammaIBA
11/2021 - 10/2019
2Lysine (L-Lysine)FDA Link
08/2021 - 01/2019
2Coloring Agents (Dyes)IBA
07/2021 - 01/2017
2Pharmaceutical PreparationsIBA
06/2021 - 01/2019
2Biological ProductsIBA
01/2021 - 01/2010
2Metalloproteases (Metalloproteinases)IBA
01/2020 - 05/2019
2ProdrugsIBA
10/2015 - 01/2006
2Peptides (Polypeptides)IBA
01/2015 - 02/2002
2EnzymesIBA
04/2013 - 02/2002
2von Willebrand FactorIBA
12/2012 - 07/2009
2Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
12/2004 - 10/2004
1Amyloid (Amyloid Fibrils)IBA
12/2022
1Sirtuin 2IBA
12/2022
1RNA (Ribonucleic Acid)IBA
12/2021
1TinIBA
11/2021
1NitrogenIBA
11/2021
1titanium nitride (titanium nitride (TiN))IBA
11/2021
1cinnamaldehyde (cinnamic aldehyde)FDA Link
08/2021
1AntioxidantsIBA
08/2021
1Therapeutic UsesIBA
08/2021
1pimonidazoleIBA
08/2021
1Glutathione (Reduced Glutathione)IBA
08/2021
1NitroimidazolesIBA
08/2021
1Reactive Oxygen Species (Oxygen Radicals)IBA
08/2021
1Matrix Metalloproteinase 14 (MT1-MMP)IBA
01/2020
1Antineoplastic Agents (Antineoplastics)IBA
01/2020
1Tissue Inhibitor of Metalloproteinase-2IBA
01/2020
1ChloridesIBA
10/2019
1Peroxisome Proliferator-Activated Receptors (PPAR)IBA
10/2019
11,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA
05/2019
1Heparin (Liquaemin)FDA LinkGeneric
01/2019
1Fibronectins (Fibronectin)IBA
01/2019
1CollagenIBA
12/2017
1PolymersIBA
02/2017
1Proprotein Convertases (Pro-Opiomelanocortin Converting Enzyme)IBA
10/2015
1Serine Proteases (Serine Protease)IBA
10/2015
1Apolipoproteins E (ApoE)IBA
03/2015
1Matrix Metalloproteinase InhibitorsIBA
03/2015
1Capsules (Microcapsules)IBA
01/2015
1Cytotoxins (Cytolysins)IBA
09/2014
1UbiquitinIBA
04/2013
1Paclitaxel (Taxol)FDA LinkGeneric
02/2013

Therapy/Procedure

13Therapeutics
11/2021 - 02/2002
5Stents
04/2022 - 05/2014
3Drug-Eluting Stents
01/2021 - 02/2017
2Aftercare (After-Treatment)
01/2020 - 08/2003
1Intravitreal Injections
12/2021
1Photothermal Therapy
11/2021
1Precision Medicine
01/2021
1Injections
01/2020
1Intravenous Administration
10/2019